- Home
- ANGO vs INBX Comparison
ANGO vs INBX Comparison
Compare ANGO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- INBX
- Stock Information
- Founded
- ANGO 1988
- INBX 2010
- Country
- ANGO United States
- INBX United States
- Employees
- ANGO N/A
- INBX N/A
- Industry
- ANGO Medical/Dental Instruments
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- INBX Health Care
- Exchange
- ANGO Nasdaq
- INBX Nasdaq
- Market Cap
- ANGO 271.1M
- INBX 222.5M
- IPO Year
- ANGO 2004
- INBX 2020
- Fundamental
- Price
- ANGO $7.20
- INBX $16.21
- Analyst Decision
- ANGO Strong Buy
- INBX Hold
- Analyst Count
- ANGO 4
- INBX 1
- Target Price
- ANGO $12.00
- INBX N/A
- AVG Volume (30 Days)
- ANGO 515.1K
- INBX 47.7K
- Earning Date
- ANGO 01-03-2025
- INBX 08-13-2024
- Dividend Yield
- ANGO N/A
- INBX N/A
- EPS Growth
- ANGO N/A
- INBX N/A
- EPS
- ANGO N/A
- INBX 118.83
- Revenue
- ANGO $292,726,000.00
- INBX $1,687,000.00
- Revenue This Year
- ANGO N/A
- INBX N/A
- Revenue Next Year
- ANGO $7.69
- INBX N/A
- P/E Ratio
- ANGO N/A
- INBX $0.14
- Revenue Growth
- ANGO N/A
- INBX 24.26
- 52 Week Low
- ANGO $5.26
- INBX $10.80
- 52 Week High
- ANGO $8.25
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ANGO 56.31
- INBX 56.54
- Support Level
- ANGO $6.61
- INBX $15.24
- Resistance Level
- ANGO $7.46
- INBX $16.79
- Average True Range (ATR)
- ANGO 0.33
- INBX 0.59
- MACD
- ANGO 0.08
- INBX 0.02
- Stochastic Oscillator
- ANGO 73.74
- INBX 62.56
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.